April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Comparison Of Unjectable Abobotulinumtoxina And Onabotulinumtoxina For Treatment Of Lateral Orbital Rhitindes
Author Affiliations & Notes
  • Yasmin Shayesteh
    Ophthalmology, George Washington University, Washington, Dist. of Columbia
  • Footnotes
    Commercial Relationships  Yasmin Shayesteh, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1063. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yasmin Shayesteh; Comparison Of Unjectable Abobotulinumtoxina And Onabotulinumtoxina For Treatment Of Lateral Orbital Rhitindes. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1063.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Cosmetic use of the botulinum toxin is unique to one of the seven serotypes produced by the organism Clostridium botulinum, serotype A. For several years, Botox was the only approved form of injectable botulinum toxin to effectively reduced the appearance of fine lines and wrinkles. Recently, a newer formulation of botulinum toxin type A, Dysport, has been approved for cosmetic use. Although the botulinum toxin serotype is the same in Dysport and Botox, distinct differences exist in their physiochemical profiles. There is limited data comparing simultaneous use of Botox and Dysport in patients to demonstrate differences in their clinical effect. Our purpose is to compare the outcomes of intramuscular Dysport and Botox injections for the cosmetic treatment of lateral orbital rhitindes.

Methods: : 25 patients who presented to a private oculoplastic surgery practice pursuing cosmetic reduction of fine lines were enrolled in the study. Using a single-blinded approach, participants received simultaneous injections of Dysport and Botox to treat lateral orbital rhitindes on opposite sides. Outcome measures included pain during injection, time to effect and loss of effect, reduction of fine lines and wrinkles, side effects, and overall patient satisfaction. These measures were assessed with patient questionnaires.

Results: : Among the 25 patients, 50% experienced less pain with Dysport injections, 35% with Botox injections, and the pain at the time of injection in the remaining 15% was equal on both sides. 27% observed a shorter time to effect, with Dysport injections, with a mean of 11.7 days with the remaining patients noting no difference in the time from injection to effect on either side. There was no considerable difference in the time to subjective loss of effect with Dysport lasting an average of 50 days and Botox lasting 49 days, on average. 60% of participants noted fewer wrinkles and fine lines on the side treated with Dysport and 20% found no difference between the two sides. 30% of patients noted bruising following Botox injection, the remainder noted no side effects.

Conclusions: : Dysport and Botox, as demonstrated in our small group of patients, is comparable in effect for treating lateral orbital rhitindes. Dysport injection may cause less pain and bruising and may have a faster onset of action.

Keywords: injection • eyelid • aging 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.